Gastrointestinal stromal tumors (GIST), the most common sarcomas of the gastrointestinal tract, are primarily driven by c-KIT or PDGFRA mutations that activate downstream signaling pathways, including PI3K/AKT/mTOR. Whereas imatinib (IM), a first-line tyrosine kinase inhibitor (TKI), is initially effective, resistance develops in ∼50% of patients within 20 months. Second- and third-line TKIs, such as sunitinib and regorafenib, provide limited benefits, highlighting the urgent need to address resistance mechanisms. Previous research has predominantly focused on genetic drivers of resistance and overlooked the role of the tumor microenvironment. In this study, we identified a role for cancer-associated fibroblasts (CAF) in driving IM resistance. Specifically, TGFβ1 secreted by CAFs amplified cellular communication network factor 2 (CCN2)/receptor for activated C kinase 1 (Rack1) signaling. The CCN2/Rack1 axis activated PI3K/AKT signaling to induce phosphorylation and mitochondrial translation of phosphoglycerate kinase 1 (PGK1), promoting metabolic reprogramming that supported tumor survival and drug resistance. Coculture models and single-cell RNA sequencing revealed distinct CAF subtypes and showed that CAF-secreted TGFβ1 enhanced glycolysis and inhibited the tricarboxylic acid cycle, fueling GIST progression and secondary resistance. Inversely, CCN2 secreted by GIST cells promoted TGFβ1 production in CAFs. These findings uncover a TGFβ1/CCN2/Rack1/PGK1 mechanism linking CAF-mediated metabolic reprogramming to IM resistance in GISTs. Targeting CAF–GIST interactions and key metabolic pathways presents a promising therapeutic strategy. Significance: Cross-talk between cancer-associated fibroblasts and cancer cells promotes metabolic and tumor microenvironmental reprogramming that drives imatinib resistance in gastrointestinal stromal tumors, providing potential targets to overcome resistance and improve therapeutic outcomes.
Background: The optimal duration of preoperative imatinib (IM) remains controversial. This study aimed to evaluate the safety, therapeutic effectiveness, and optimal duration of preoperative IM in patients with locally advanced gastric gastrointestinal stromal tumors (GIST).Methods: The clinicopathologic data of 41 patients with locally advanced gastric GIST who received preoperative IM and underwent surgical resection from January 2014 and December 2021 were retrospectively analyzed.Results: After a median of 7.0 (IQR: 4.5–10) months of preoperative IM treatment, 30 patients experienced adverse events (AEs), 80% of which were grade 1/2 AEs. The mean tumor size decreased from 12.71 ± 5.34 cm to 8.26 ± 4.00 cm, with a reduction rate of 35%. Setting 8 months as the cut‐off value according to the results of ROC analysis. The proportion of laparoscopic surgery was higher in patients with short‐term (≤8 months) versus long‐term (>8 months) preoperative IM. Compared with the subtotal/total gastrectomy group, patients in the local gastrectomy group exhibited less intraoperative blood loss, shorter length of postoperative hospital stay, and fewer postoperative complications. The 3‐year recurrence‐free survival (RFS) and overall survival (OS) rates were 82.9% and 97.6%, and the expected 5‐year RFS and OS rates were 75.6% and 90.2% respectively. RFS was better in the short‐term than in the long‐term preoperative IM treatment group, and it was also better in pre‐ plus postoperative IM treatment group than that in the preoperative IM alone group. Both univariate and multivariate COX analysis showed that a higher mitotic index and long‐term preoperative IM treatment were associated with worse RFS, while postoperative IM treatment could significantly improve RFS.Conclusions: The study suggests that in patients with locally advanced gastric GIST, preoperative short‐term (≤8 months) use of IM is associated with higher RFS than long‐term use.